Spinal Cord InjuriesNCT04217577
Dried Plum Supplementation as Treatment for Bone Loss Following Spinal Cord Injury
A study testing Dried plums in people with Spinal Cord Injuries, run by VA Palo Alto Health Care System at 1 site in United States.
Trial summary
The purpose of this pilot study is to explore whether dried plum (prunes) added to the diet is effective in reducing or reversing bone loss following spinal cord injury (SCI). The investigators will look for changes in bone mineral density as well as evidence in the blood of markers of bone activity. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Spinal Cord Injuries
- What is being tested?
- Dried plums
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Jan 2019to 20 Mar 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- SCI at any level, America Spinal injury Association (ASIA) Impairment Scale = A-C
- Primarily wheelchair-user
- Age - between 18 and 65 years old.
- Two cohorts will be recruited:
- chronic injury greater than 4 yr and
- newly injured, less than 4 years
- The investigators will target Vit D blood level to be 20 ng/ml or higher and suggest that any potential participants with Vit D greater than 10 but below 20 receive a clinical protocol to achieve 20 ng/ml.
Who cannot join
- Presence of hyper/hypo-parathyroidism, renal insufficiency (GFR<60ml/min), currently taking hormone replacement therapy, severe vitamin D deficiency (<10 ng/ml), thyroid disease, active cancer diagnosis, currently using bisphosphonate or parathyroid hormone therapy, diagnosed fracture less than 3 months ago, current pressure sore stage III or IV, New York Heart Association (NYHA) functional classification of stage II-IV, inflammatory bowel disease, cirrhosis of the liver, consuming more than 3 dried plums/day as their regular diet.
- Vitamin D blood level below 10 ng/ml
Trial locations and contacts
1 site in 1 country.
United States1 site
VA Palo Alto Health Care System
Palo Alto, California, 94304
About this study
The purpose of this pilot study is to explore whether dried plum (prunes) added to the diet is effective in reducing or reversing bone loss following spinal cord injury (SCI). The investigators will look for changes in bone mineral density as well as evidence in the blood of markers of bone activity. The first part of the study is to check whether participants with SCI can and will eat the required amount of dried plums (prunes) on a daily basis. The second part of the study is to follow participants over one year and look for changes in bone mass and blood markers.
Read the detailed description
Recruitment \& screening: SCI clinicians will invite patients from the VA SCI Center census to participate in the pilot in person during a clinic visit or inpatient admission. If the patient is interested, one of the study team will explain the study and obtain consent. The study will be performed on an outpatient basis with return to the VA for study visits at 3, 6 ,9 , and 12 months.
The investigators will mail Opt-Out Letters to individuals who have been identified as potentially eligible. The Opt-Out Letter will include a Response Letter and a Return Self-addressed Stamped Envelope (attached). If the investigators do not receive a NO response by phone or mail after 2 weeks, they will attempt to call using an Opt-Out Telephone Script and Recruitment Script (Attached).
Screening is primarily done based on interest, medical history and contraindications. There may be blood values, collected at baseline that indicate ineligibility, but these will be determined on individual cases. Interest in the study and commitment to maintain the study diet/intake will be important to ascertain - although the investigators anticipate that there may be dropout or reduced compliance with time.
Procedures:
- For the first month, each participant will consume 6-8 prunes per day to determine tolerability. Starting in Month 2, each participant will consume approximately 10-16 prunes/day (<120 g), depending on the size of the prune. The smaller prunes weigh about 7 g and the larger weigh up to 10 g. It will be suggested to consume 5-8 prunes twice per day for breakfast and dinner. However, this is not a requirement, so long as the per-day goal is met. If a participant does not eat the daily requirement one day they will be encouraged to make up the difference over the next 6 days such that the total is equal to the required 100-112 total prunes for the week. If however, they miss multiple days of prune consumption, they will be asked to contact the study coordinators to develop a reasonable plan to get back on track.
- Participants will be asked to track consumption regularly by use of a chart. They will be instructed to note days when they missed or consumed fewer prunes. They will also be instructed to note any changes in bowel or other function and contact study staff with any questions.
Assessments:
- Bone mineral density by dual xray absorptiometry (DXA) to include the following sites: total body, spine, bilateral hip, bilateral knee. Total body scans will be obtained at baseline and at 12 months; all other scans will be obtained at baseline, 3, 6, 9, and 12 months.
- Blood assessments will be collected at the same intervals and will include serum concentrations of C-terminal telopeptide (CTX), which is a bone resorption marker, and Procollagen Type I Intact N-Terminal Propeptide (P1NP), a bone formation marker to measure the rate and direction of bone metabolism during the study. Serum will be frozen for batch processing. Safety labs will also be drawn including a comprehensive metabolic panel, primarily to monitor renal function, calcium concentration, and blood sugar. Magnesium and phosphorus levels will also be analyzed. De-identified, coded blood samples will be sent to Quest Diagnostics Lab (contracting lab) for analysis.
- Surveys will be administered to the participants at 0, 3, 6, 9, and 12 months. These will include the Global Health Scale- to evaluate overall health and well-being, the Spinal Cord Injury Quality of Life Questionnaire (SCI-QOL) on Bowel Management as well as the Bristol Stool Chart-to ascertain any affects the consumption of prunes have on participants' bowel habits. Finally participants will be given a brief questionnaire regarding their activity level, general health status, lifestyle habits, and participation characteristics while in the study.
Study Contact: For the first month, study staff will call each participant weekly to ask about any concerns or issues related to prune consumption. After this, calls will be less frequent, biweekly for the next month(s) and once per month after this. As this is a pilot study, the investigators may adjust the call frequency as needed to determine if more or fewer calls are needed. One of the main goals of this pilot is to determine feasibility related to regular consumption; the investigators feel that useful information can be gathered by calling rather than waiting for the participant to contact us.
- Conditions
- Spinal Cord Injuries
- Being tested
- Dried plums
- Medical subject headings
- Spinal Cord Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dried plumsDietary supplement
10-16 dried plums/day, approximately 100-120 g/day
| Study group | Role | What they receive |
|---|---|---|
| Dried Plums | Experimental | Consume dried plums daily. Receives: Dietary Supplement: Dried plums |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Procollagen Type I Intact N-Terminal Propeptide (P1NP)
Blood marker of bone formation
Measured: change from baseline to 12 months
Change in C-terminal telopeptide (CTX)
Blood marker of bone resorption
Measured: change from baseline to 12 months
Change in Bone mineral density (BMD) - multiple sites
BMD of hip and knee
Measured: change from baseline to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2020
- Study start20 Jan 2019
- Primary completion20 Mar 2020
- Study completion20 Mar 2020
Why it stopped: Restriction on in-person research due to COVID-19
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal Cord InjuriesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Palo Alto Health Care System
- Sponsor type
- US federal agency
- Responsible party
- Principal investigator, Beatrice Jenny Kiratli PhD, VA Palo Alto Health Care System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04217577
- Sponsor's protocol ID
- KIB0033
- Status last verified
- Oct 2021
- First submitted
- 30 Dec 2019
- Last updated
- 25 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: This is very preliminary and we are not sure yet if sharing will be valuable as we may make protocol amendments depending on study data.
Study at a glance
From the registry record, last updated by the sponsor on 25 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dried Plum Supplementation as Treatment for Bone Loss Following Spinal Cord Injury
- ClinicalTrials.gov ID
- NCT04217577
- Acronym / sponsor ID
- KIB0033
- Conditions
- Spinal Cord Injuries
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Restriction on in-person research due to COVID-19
- Enrolment
- 4 participants (actual)
- Lead sponsor
- VA Palo Alto Health Care SystemUS federal agency
- Study start
- 20 Jan 2019 (actual)
- Primary completion
- 20 Mar 2020 (actual)
- Study completion
- 20 Mar 2020 (actual)
- First posted
- 3 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this pilot study is to explore whether dried plum (prunes) added to the diet is effective in reducing or reversing bone loss following spinal cord injury (SCI). The investigators will look for changes in bone mineral density as well as evidence in the blood of markers of bone activity. The first part of the study is to check whether participants with SCI can and will eat the required amount of dried plums (prunes) on a daily basis. The second part of the study is to follow participants over one year and look for changes in bone mass and blood markers.
Detailed description
Recruitment \& screening: SCI clinicians will invite patients from the VA SCI Center census to participate in the pilot in person during a clinic visit or inpatient admission. If the patient is interested, one of the study team will explain the study and obtain consent. The study will be performed on an outpatient basis with return to the VA for study visits at 3, 6 ,9 , and 12 months.
The investigators will mail Opt-Out Letters to individuals who have been identified as potentially eligible. The Opt-Out Letter will include a Response Letter and a Return Self-addressed Stamped Envelope (attached). If the investigators do not receive a NO response by phone or mail after 2 weeks, they will attempt to call using an Opt-Out Telephone Script and Recruitment Script (Attached).
Screening is primarily done based on interest, medical history and contraindications. There may be blood values, collected at baseline that indicate ineligibility, but these will be determined on individual cases. Interest in the study and commitment to maintain the study diet/intake will be important to ascertain - although the investigators anticipate that there may be dropout or reduced compliance with time.
Procedures:
- For the first month, each participant will consume 6-8 prunes per day to determine tolerability. Starting in Month 2, each participant will consume approximately 10-16 prunes/day (<120 g), depending on the size of the prune. The smaller prunes weigh about 7 g and the larger weigh up to 10 g. It will be suggested to consume 5-8 prunes twice per day for breakfast and dinner. However, this is not a requirement, so long as the per-day goal is met. If a participant does not eat the daily requirement one day they will be encouraged to make up the difference over the next 6 days such that the total is equal to the required 100-112 total prunes for the week. If however, they miss multiple days of prune consumption, they will be asked to contact the study coordinators to develop a reasonable plan to get back on track.
- Participants will be asked to track consumption regularly by use of a chart. They will be instructed to note days when they missed or consumed fewer prunes. They will also be instructed to note any changes in bowel or other function and contact study staff with any questions.
Assessments:
- Bone mineral density by dual xray absorptiometry (DXA) to include the following sites: total body, spine, bilateral hip, bilateral knee. Total body scans will be obtained at baseline and at 12 months; all other scans will be obtained at baseline, 3, 6, 9, and 12 months.
- Blood assessments will be collected at the same intervals and will include serum concentrations of C-terminal telopeptide (CTX), which is a bone resorption marker, and Procollagen Type I Intact N-Terminal Propeptide (P1NP), a bone formation marker to measure the rate and direction of bone metabolism during the study. Serum will be frozen for batch processing. Safety labs will also be drawn including a comprehensive metabolic panel, primarily to monitor renal function, calcium concentration, and blood sugar. Magnesium and phosphorus levels will also be analyzed. De-identified, coded blood samples will be sent to Quest Diagnostics Lab (contracting lab) for analysis.
- Surveys will be administered to the participants at 0, 3, 6, 9, and 12 months. These will include the Global Health Scale- to evaluate overall health and well-being, the Spinal Cord Injury Quality of Life Questionnaire (SCI-QOL) on Bowel Management as well as the Bristol Stool Chart-to ascertain any affects the consumption of prunes have on participants' bowel habits. Finally participants will be given a brief questionnaire regarding their activity level, general health status, lifestyle habits, and participation characteristics while in the study.
Study Contact: For the first month, study staff will call each participant weekly to ask about any concerns or issues related to prune consumption. After this, calls will be less frequent, biweekly for the next month(s) and once per month after this. As this is a pilot study, the investigators may adjust the call frequency as needed to determine if more or fewer calls are needed. One of the main goals of this pilot is to determine feasibility related to regular consumption; the investigators feel that useful information can be gathered by calling rather than waiting for the participant to contact us.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dried Plums | Experimental | Dietary Supplement: Dried plumsConsume dried plums daily. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- SCI at any level, America Spinal injury Association (ASIA) Impairment Scale = A-C
- Primarily wheelchair-user
- Age - between 18 and 65 years old.
- Two cohorts will be recruited:
- The investigators will target Vit D blood level to be 20 ng/ml or higher and suggest that any potential participants with Vit D greater than 10 but below 20 receive a clinical protocol to achieve 20 ng/ml.
Key exclusion criteria (2 listed)
- Presence of hyper/hypo-parathyroidism, renal insufficiency (GFR<60ml/min), currently taking hormone replacement therapy, severe vitamin D deficiency (<10 ng/ml), thyroid disease, active cancer diagnosis, currently using bisphosphonate or parathyroid hormone therapy, diagnosed fracture less than 3 months ago, current pressure sore stage III or IV, New York Heart Association (NYHA) functional classification of stage II-IV, inflammatory bowel disease, cirrhosis of the liver, consuming more than 3 dried plums/day as their regular diet.
- Vitamin D blood level below 10 ng/ml
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dried plums10-16 dried plums/day, approximately 100-120 g/day | Dietary supplement | Dried Plums |
Primary outcome
Change in Procollagen Type I Intact N-Terminal Propeptide (P1NP)
Time frame: change from baseline to 12 months
Blood marker of bone formation
Change in C-terminal telopeptide (CTX)
Time frame: change from baseline to 12 months
Blood marker of bone resorption
Change in Bone mineral density (BMD) - multiple sites
Time frame: change from baseline to 12 months
BMD of hip and knee
Results and safety
The study was stopped early (reason given: Restriction on in-person research due to COVID-19). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Oct 2021.
- Individual participant dataSharing planned: Undecided. This is very preliminary and we are not sure yet if sharing will be valuable as we may make protocol amendments depending on study data.
Related trials for Spinal Cord Injuries
Recruiting
MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury
Spinal Cord Injuries, Tetraplegia
Recruiting
Clinical Outcome Assessment for AT & BCI
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Recruiting
Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCI
Spinal Cord Injuries
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Chronic Spinal Cord Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dried plums in people with Spinal Cord Injuries, run by VA Palo Alto Health Care System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 25 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Restriction on in-person research due to COVID-19). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Procollagen Type I Intact N-Terminal Propeptide (P1NP) (time frame: change from baseline to 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2021.